• About
    • About
    • Leadership
  • Science
    • Product
    • Pipeline
    • Publications
    • Clinical Trials
  • News
  • Careers
  • Contact
Restoring balance to the immune system
  • About
    • About
    • Leadership
  • Science
    • Product
    • Pipeline
    • Publications
    • Clinical Trials
  • News
  • Careers
  • Contact

Press Releases

By PG
In Press Releases
Posted September 2, 2021

Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced [...]

Read More
By PG
In Press Releases
Posted March 30, 2021

Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort [...]

Read More
By PG
In Press Releases
Posted November 23, 2020

Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the first subject has been enrolled in its [...]

Read More
By PG
In Press Releases
Posted October 8, 2020

Sentien-Led Team Awarded $2.4M Contract from the U.S. DoD and MTEC

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, has been awarded a $2.4 million contract from the Medical [...]

Read More
By PG
In Press Releases
Posted August 18, 2020

Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) [...]

Read More
By PG
In Press Releases
Posted July 9, 2020

Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., [...]

Read More
By PG
In Press Releases
Posted May 15, 2020

Sentien Biotechnologies Names Richard Ganz as Executive Chairman

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive [...]

Read More
By PG
In Press Releases
Posted June 8, 2017

Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for [...]

Read More
By jguettler
In Press Releases
Posted April 4, 2017

Sentien Biotechnologies, Inc. Announces $12 Million Series A Financing

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The [...]

Read More
Sentien Biotechnologies, Inc.
99 Hayden Avenue
Building E, Suite 140
Lexington, MA 02421

+1-781-361-9031
info@sentienbiotech.com
Connect With Us
Home About About Leadership Boards Science Product Pipeline Publications Clinical Trials
News Careers Contact
Copyright © Privacy Policy Terms of Use Site Design: Monderer Design